Pablo Martinez-Martin1, Anette Schrag2, Daniel Weintraub3,4, Alexandra Rizos5,6, Carmen Rodriguez-Blazquez1, Kallol Ray Chaudhuri5,6. 1. National Center of Epidemiology and CIBERNED Carlos III Institute of Health Madrid Spain. 2. Department of Clinical Neurosciences, Royal Free Campus Institute of Neurology University College London London United Kingdom. 3. Departments of Psychiatry and Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA. 4. Parkinson's Disease Research Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center Philadelphia Pennsylvania USA. 5. Parkinson's Foundation International Centre of Excellence King's College Hospital London United Kingdom. 6. Institute of Psychiatry, Psychology and Neuroscience King's College London London United Kingdom.
Abstract
BACKGROUND: Non-motor symptoms (NMS) are integral to Parkinson's disease (PD) and have a detrimental effect on patients and their caregivers. Clinical quantification has been aided by the development of comprehensive assessments such as the Non-Motor Symptoms Questionnaire (NMSQuest) and Scale (NMSS). The NMSS has been widely used in clinical studies and trials; however, since its validation in 2007, our understanding of NMS has changed substantially. With the support of the International Parkinson and Movement Disorder Society (IPMDS), after a detailed peer review an initiative to develop an updated version of NMSS, the MDS-NMS was launched in 2015. OBJECTIVE: This paper encapsulates the data from the pre-validation phases carried out under the auspices of the IPMDS Non-Motor PD Study Group. METHODS: Item selection and wording (formatted as a rater-based tool) were based on the NMSS, literature review, and expert consensus. Neurologists, PD patients, and healthy controls were included in the cognitive pretesting and administration of the preliminary version of the MDS-NMS. Primary data on acceptability and reliability were obtained. RESULTS: The pilot study, carried out in English in the United Kingdom and the United States, demonstrated that the preliminary version of the MDS-NMS was comprehensive, understandable, and appropriate. Data quality was excellent; moderate floor effect was present in patients for most MDS-MNS domains, with some components showing weak internal consistency. The results led to additional instrument modifications. CONCLUSION: Qualitative and quantitative research results have led to an updated NMSS, the definitive version of the MDS-NMS, which is currently being validated.
BACKGROUND: Non-motor symptoms (NMS) are integral to Parkinson's disease (PD) and have a detrimental effect on patients and their caregivers. Clinical quantification has been aided by the development of comprehensive assessments such as the Non-Motor Symptoms Questionnaire (NMSQuest) and Scale (NMSS). The NMSS has been widely used in clinical studies and trials; however, since its validation in 2007, our understanding of NMS has changed substantially. With the support of the International Parkinson and Movement Disorder Society (IPMDS), after a detailed peer review an initiative to develop an updated version of NMSS, the MDS-NMS was launched in 2015. OBJECTIVE: This paper encapsulates the data from the pre-validation phases carried out under the auspices of the IPMDS Non-Motor PD Study Group. METHODS: Item selection and wording (formatted as a rater-based tool) were based on the NMSS, literature review, and expert consensus. Neurologists, PD patients, and healthy controls were included in the cognitive pretesting and administration of the preliminary version of the MDS-NMS. Primary data on acceptability and reliability were obtained. RESULTS: The pilot study, carried out in English in the United Kingdom and the United States, demonstrated that the preliminary version of the MDS-NMS was comprehensive, understandable, and appropriate. Data quality was excellent; moderate floor effect was present in patients for most MDS-MNS domains, with some components showing weak internal consistency. The results led to additional instrument modifications. CONCLUSION: Qualitative and quantitative research results have led to an updated NMSS, the definitive version of the MDS-NMS, which is currently being validated.
Entities:
Keywords:
MDS‐NMS; Parkinson's disease; new non‐motor symptoms scale; non‐motor symptoms; pilot study
Authors: Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang Journal: Arch Neurol Date: 2010-05
Authors: Neil Aaronson; Jordi Alonso; Audrey Burnam; Kathleen N Lohr; Donald L Patrick; Edward Perrin; Ruth E Stein Journal: Qual Life Res Date: 2002-05 Impact factor: 4.147
Authors: Kallol Ray Chaudhuri; Pablo Martinez-Martin; Richard G Brown; Kapil Sethi; Fabrizio Stocchi; Per Odin; William Ondo; Kazuo Abe; Graeme Macphee; Doug Macmahon; Paolo Barone; Martin Rabey; Alison Forbes; Kieran Breen; Susanne Tluk; Yogini Naidu; Warren Olanow; Adrian J Williams; Sue Thomas; David Rye; Yoshio Tsuboi; Annette Hand; Anthony H V Schapira Journal: Mov Disord Date: 2007-10-15 Impact factor: 10.338
Authors: Kallol Ray Chaudhuri; Pablo Martinez-Martin; Anthony H V Schapira; Fabrizio Stocchi; Kapil Sethi; Per Odin; Richard G Brown; William Koller; Paolo Barone; Graeme MacPhee; Linda Kelly; Martin Rabey; Doug MacMahon; Sue Thomas; William Ondo; David Rye; Alison Forbes; Susanne Tluk; Vandana Dhawan; Annette Bowron; Adrian J Williams; Charles W Olanow Journal: Mov Disord Date: 2006-07 Impact factor: 10.338
Authors: S C Smith; D L Lamping; S Banerjee; R Harwood; B Foley; P Smith; J C Cook; J Murray; M Prince; E Levin; A Mann; M Knapp Journal: Health Technol Assess Date: 2005-03 Impact factor: 4.014
Authors: P Martinez-Martin; C Rodriguez-Blazquez; K Abe; K B Bhattacharyya; B R Bloem; F J Carod-Artal; R Prakash; R A J Esselink; C Falup-Pecurariu; M Gallardo; P Mir; Y Naidu; A Nicoletti; K Sethi; Y Tsuboi; J J van Hilten; M Visser; M Zappia; K R Chaudhuri Journal: Neurology Date: 2009-11-10 Impact factor: 9.910
Authors: Claudia Trenkwalder; Bryan Kies; Monika Rudzinska; Jennifer Fine; Janos Nikl; Krystyna Honczarenko; Peter Dioszeghy; Dennis Hill; Tim Anderson; Vilho Myllyla; Jan Kassubek; Malcolm Steiger; Marco Zucconi; Eduardo Tolosa; Werner Poewe; Erwin Surmann; John Whitesides; Babak Boroojerdi; Kallol Ray Chaudhuri Journal: Mov Disord Date: 2010-11-18 Impact factor: 10.338
Authors: K Ray Chaudhuri; Anette Schrag; Daniel Weintraub; Alexandra Rizos; Carmen Rodriguez-Blazquez; Eugenia Mamikonyan; Pablo Martinez-Martin Journal: Mov Disord Date: 2019-09-30 Impact factor: 10.338
Authors: Mariana H G Monje; Rebecca L M Fuller; Esther Cubo; Tiago A Mestre; Ai Huey Tan; Julie C Stout; Shazia Ali; Lana Chahine; Kathy Dujardin; Cheryl J Fitzer-Attas; Jinyoung Youn; Bastiaan R Bloem; Fay B Horak; Aristide Merola; Ralf Reilmann; Serene S Paul; Earl Ray Dorsey; Walter Maetzler; Alberto J Espay; Pablo Martinez-Martin; Glenn T Stebbins; Álvaro Sánchez-Ferro Journal: Mov Disord Clin Pract Date: 2020-12-28
Authors: Jade E Kenna; Megan C Bakeberg; Anastazja M Gorecki; Alfred Chin Yen Tay; Samantha Winter; Frank L Mastaglia; Ryan S Anderton Journal: Mov Disord Clin Pract Date: 2021-01-05
Authors: Daniel J van Wamelen; Anna Sauerbier; Valentina Leta; Carmen Rodriguez-Blazquez; Cristian Falup-Pecurariu; Mayela Rodriguez-Violante; Alexandra Rizos; Y Tsuboi; Vinod Metta; Roongroj Bhidayasiri; Kalyan Bhattacharya; Rupam Borgohain; L K Prashanth; Raymond Rosales; Simon Lewis; Victor Fung; Madhuri Behari; Vinay Goyal; Asha Kishore; Santiago Perez Lloret; Pablo Martinez-Martin; K Ray Chaudhuri Journal: Sci Rep Date: 2021-05-05 Impact factor: 4.379
Authors: Daniel Johannes van Wamelen; Silvia Rota; Anette Schrag; Alexandra Rizos; Pablo Martinez-Martin; Daniel Weintraub; Kallol Ray Chaudhuri Journal: Mov Disord Clin Pract Date: 2022-08-05